was successfully added to your cart.

Side Effects of Vorapaxar (Zontivity)

FIND A PHARMACIST WHO OFFERS GENETIC TESTING FOR Antiplatelets

Vorapaxar, commonly known by its trade name Zontivity, is a thrombin receptor antagonist. It is used in the treatment of myocardial infarction (heart attacks). It is a type of antiplatelet medication and as such carries side effects commonly associated with this drug class.

Zontivity Common Effects Include Risk of Severe Bleeding

As an antiplatelet drug, Zontivity has a number of hematological effects that may become pathogenic. According to the Zontivity Label as reported by the FDA, common side effects include:

  • Severe, sometimes fatal bleeding (hemorrhage)
  • Anemia (low red blood cell count)
  • Rashes
  • Eruptions (skin condition)
  • Gastrointestinal bleeding
  • Diplopia (double vision)
  • Although it is rare, some cases of intracranial bleeding have been reported along with the other severe reactions such as death.

    Know Your Risk for Side Effects with the Rxight® Genetic Test

    Pharmacogenetics, the study of how an individual’s genes affect the therapeutic and adverse medications, has been identified as a major contributor to the response exhibited by patients when taking medications. Polymorphisms in genes coding for enzymes and receptors can increase the probability of being a non-responder to the drug or developing adverse effects. Thus, there is variable difference between patients using the medication.

    How Does Pharmacogenetic Testing Work?

    Identifying these polymorphisms is crucial in clinical decision making. A doctor may alter the dose of vorapaxar or discontinue treatment given a patient’s known alleles.

    Rxight® pharmacogenetics testing sequences 18 genes (includin cytochrome P450 enzymes such as CYP3A4) to establish how patients are likely to react to hundreds of clinically relevant medications (including antiplatelet agents like Vorapaxar). Contact us today for more information on Rxight® pharmacogenetic testing.

    Contributors to this Article:
    Michael Sapko, MD, PhD; Deborah Kallick, PhD, Medicinal Chemistry

    Read more about Rxight® Drug Sensitivity Testing